Terns Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2021-02-04

Reporting Person: Vignola Mark J. (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$6.86	2030-09-09	Common Stock (76995)		Direct
Stock Option (Right to Buy)	$9.24	2030-12-29	Common Stock (150812)		Direct

Footnotes

F1: This option is early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from September 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

F2: Reflects a 1-for-14 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F3: This option is early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from December 30, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.